Cancer Therapy Advisor (9/1, Blevins Primeau) reported, “The prevalence of metastatic cancers in the United States has risen in recent years and is expected to increase further by 2025, according to a study.” The findings were published in the Journal of the National Cancer Institute. […]
Healio (8/12, Byrne) reported researchers “have developed an automated liquid biopsy test that can detect cancer DNA in the blood of patients with metastatic breast cancer within 5 hours.” The tool dubbed “Liquid Biopsy for Breast Cancer Methylation (LBx-BCM) works with a currently available molecular testing platform, GeneXpert (Cepheid), and can detect methylation in one or […]
MedPage Today (7/27, Bassett) reported, “Frequent aspirin use was associated with a decreased risk of ovarian cancer, even in the presence of risk factors, according to a…meta-analysis.” In total, “frequent aspirin use was associated with a 13% reduction in ovarian cancer risk…across 17 studies, with no difference between cohort and case-control study results…reported” researchers. Also, “risk […]
Oncology Nurse Advisor (7/19, Larson) reported that research “showed incidence of” cervical intraepithelial neoplasia grade 3 or higher “and cervical cancer is approximately 74% lower after a negative HPV screen than after a negative cytology screen in women aged 24 to 49 years.” Investigators “found that the incidence of CIN3+ at subsequent screening after a negative […]
Cancer Therapy Advisor (7/8, Dembeck) reported, “Many patients with advanced ovarian cancer may be eligible for first-line maintenance with a PARP inhibitor, according to research.” Investigators “also found that patients treated with bevacizumab and those who have BRCA mutations are likely to have better outcomes.” The findings were published in Cancer. […]
Oncology Nursing News (6/14, Fischer) reported, “Patients with ovarian cancer treated with FDA-approved PARP inhibitors had significant differences in the incidence of clinically relevant adverse events (AEs), according to results of a real-world analysis.” The findings were presented at the 2022 ASCO Annual Meeting. […]
HealthDay (5/27) reported that “the appearance of ovarian lesions on ultrasound may predict the risk for malignancy, according to a” retrospective cohort study. The study – published in Radiology – “included isolated ovarian lesions identified at pelvic ultrasound to examine whether an ultrasound-based classification scheme of classic versus nonclassic appearance can be used to help appropriately triage women […]
Healio (5/13, Lawrence) reported, “A decrease in cervical cancer rates in the United States, most notably among younger women, may be associated with HPV vaccination approval, according to a retrospective, cross-sectional study.” The research was published in JAMA Network Open. […]
Cancer Therapy Advisor (5/6, Mistry) reported, “Adding radiotherapy (RT) to chemotherapy after surgery improves overall survival (OS) in patients with stage IV endometrial cancer, according to research.” The data indicated that “the benefit with RT was observed across all histologies except clear cell carcinoma, and the benefit was greatest when chemotherapy was combined with both external […]
HealthDay (3/16) reported, “The recent decrease in the incidence of cervical cancers, particularly in young women, may be associated with human papillomavirus (HPV) vaccination approval, according to a study.” Investigators “found that before vaccination approval, cervical cancer rates in the 20- to 24-year age group were decreasing at 2.29 percent annually; since approval, the rate has […]